anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Pramipexole
Trial phase: Phase 4
ATC code: N04BC05
SMILES: CCCN[C@@H]1CCc2nc(N)sc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 166
Group description: 4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase the dose to 0.25mg and to further increase or decrease the dose in steps to 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks. mode of administration: Oral, once daily in the evening (2 to 3 hours before bedtime) form: tablets
Eligibility criteria:
Inclusion Criteria:

Written informed consent consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and local Institutional Review Board/Independent Ethics Committee (IRB/IEC) requirements obtained prior to any study procedures being performed and the ability and willingness to comply with study treatment regimen and to attend study assessments
Male or female out-patients aged 18-85 years
Diagnosis of idiopathic RLS according to the clinical RLS criteria of the International Restless Legs Syndrome Study Group (IRLSSG) [P03-03355]. All four criteria must be present to fulfil the diagnosis of RLS.
RLS symptoms present at least 2 to 3 days per week during the last 3 months prior to baseline (Visit 2)
IRLS total score >15 at baseline (Visit 2)

Exclusion Criteria:

Women of child-bearing potential (i.e. premenopausal women, or postmenopausal women less than 6 months after last menses) who do not use during the clinical trial an adequate method of contraception such as: double barrier protection (e.g. diaphragm or condom and spermicide), intrauterine device, hormonal therapy (oral, injectable, or subcutaneous), or partner's surgical sterilization
Any woman of child-bearing potential not having a negative pregnancy test at screening
Breastfeeding women
Patients with known hypersensitivity to pramipexole or any other component of the investigational product or placebo tablets
Diagnosis of augmentation under previous pharmacological RLS treatment
Concomitant or previous pharmacologic therapy as follows: Any intake of dopamine agonists within 14 days prior to baseline (Visit 2); Any intake of levodopa within 14 days prior to baseline (Visit 2); Unsuccessful prior treatment with non-ergot dopamine agonists (e.g. pramipexole, ropinirole);
Intervention: Tapentadol
Trial phase: Phase 3
ATC code: N02AX06
SMILES: CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 338
Group description: Oral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses.
Eligibility criteria:
Inclusion Criteria

Male and non-pregnant, non-lactating female subjects.
Of at least 18 years of age with chronic malignant tumor-related pain with a mean pain intensity (NRS) of 5 points or higher.
Subjects who are opioid-naïve or pretreated with an equianalgesic dose range equivalent of up to 160 mg oral morphine per day and are dissatisfied with prior treatment.
Women must be postmenopausal, surgically sterile, or practicing or agree to practice an effective method of birth control throughout the trial.
Expected course of the disease and the pain that would permit compliance with the trial protocol over the entire trial period.

Exclusion Criteria

Key Exclusion Criteria:

Subjects will be excluded from the study if they have a history of seizure disorder or epilepsy;
known history and/or presence of cerebral tumor or cerebral metastases.
history of alcohol or drug abuse;
uncontrolled hypertension,
clinical laboratory values reflecting severe renal insufficiency,
moderate or severe hepatic impairment,
hepatitis B or C, HIV,
inadequate bone marrow reserve
currently treated with radiotherapy,
pain-inducing chemotherapy,
anti-parkinsonian drugs, neuroleptics, monoamine oxidase inhibitors, serotonin norepinephrine reuptake inhibitor (SNRI) or any other analgesic therapy than investigational medication or rescue medication during the trial.
selective serotonin reuptake inhibitor (SSRI) treatments are allowed if taken for at least 30 days before the screening period of the study at an unchanged dose.
Intervention: TERIPARATIDE
Trial phase: Phase 2 | Phase 3
ATC code: H05AA02
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 63
Group description: participants recieved PTH1-84 in either 100mcg daily, every other day, or every three days based on investigators clinical judgement
Eligibility criteria:
Inclusion Criteria:

Hypoparathyroidism

Exclusion Criteria:

Bisphosphonate use
Intervention: Methyl Aminolevulinate Hydrochloride
Trial phase: Phase 3
SMILES: COC(=O)CCC(=O)CN.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 102
Group description: Participants with basal cell carcinoma (BCC) lesions were administered to photodynamic therapy (PDT) with Metvix® cream 160 milligrams per gram (mg/g) applied for three hours, followed by illumination using non-coherent light with a fluency of 75 Joule per centimeter square (J/cm*2) and fluency rate of 70-200 milliwatt per centimeter square (mW/cm*2) up to 13 weeks.
Eligibility criteria:
Inclusion Criteria:

Clinical diagnosis of BCC lesions verified by histology (2-3 mm punch biopsy)
Males or females above 18 years of age.
Written informed consent. AND

Participants with high risk of surgical complications due to:

Anticoagulant medication or bleeding disorders
Cardiac risk factors
Anaesthetic contraindications
Poor surgical compliance because of participant refusal, dementia, or inability to perform wound care.

OR

• Participants with "high-risk BCC lesion(s). A "high-risk" BCC lesion is defined as:

A large BCC lesion with the largest diameter:

Equal to or greater than 15 mm on extremities, except below the knees, where largest diameter should be equal to or greater than 10 mm
Equal to or greater than 20 mm on the trunk
Equal to or greater than 15 mm in the face, or A lesion in the mid-face region (H-zone according to Swanson) or on the ear In participants with more then 6 eligible lesions, the 6 lesions to be treated was randomly chosen.

Exclusion Criteria:

Prior treatment of the lesion within 4 weeks.
A pure morpheaform and/or highly infiltrated lesion assessed clinically and/or by histology. A mixed nodular/morpheaform lesion which is not highly infiltrated (clinically) may be included.
Participant with porphyria.
Pigmented lesions.
Known allergy to Metvix® or a similar compound.
Participation in another clinical study either concurrently or within the last 30 days
Participant with Gorlin's syndrome.
Participant with Xeroderma pigmentosum
Pregnant or breast-feeding (all women of child-bearing potential must document a negative pregnancy test and use contraception during the treatments and for at least one month thereafter).
Conditions associated with a risk of poor protocol compliance.
Intervention: Paliperidone
Trial phase: Phase 3
ATC code: N05AX13
SMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 64
Group description: Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks
Eligibility criteria:
Inclusion Criteria:

Patients must satisfy the following criteria to be eligible for this study: patients with diagnoses of schizophrenia according to the DSM-IV criteria including newly diagnosed patients
Out-patients or in-patients with expected discharge within 8 weeks
Patients or their legally acceptable representatives must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from participating in the study: patients who are resistant to antipsychotic treatment
Patients who have been on clozapine or long-acting injectable antipsychotic medication during the last 3 months
Patients with CGl-S scores > 6 or who who have been hospitalized for longer than 8 continuous weeks during the past 6 months
Pregnant or breast-feeding females
Patients with a history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome.
Intervention: Chloroquine
Trial phase: Not Applicable
ATC code: P01BA01 | P01BB52
SMILES: CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 96
Group description: Subjects initially treated with Co-arthemeter, and then continued on weekly chloroquine till day 90
Eligibility criteria:
Inclusion Criteria:

All children aged 12 months to 6 years in the 13 study villages will be enrolled in the study and followed up for the duration of the study. The inclusion criteria for randomization will be:

Children aged 12 months to 6 years; and
History of fever in the preceding 48 hours or a measured temperature > 37.5oC plus asexual forms of P. falciparum in the peripheral blood film of 500/μl or above; and
Hb <110g/l and >69g/l (Our choice of the upper limit of moderate anaemia (70 - 79g/l) is to enable us assess the response to our interventions of severer forms of anaemia while at the same time reducing the risk of adverse events which might occur with lower levels of Hb).

Exclusion Criteria:

Refusal of parent or guardian to give consent to the child's participation in the study
Inability of the subjects to take oral medications
Presence of features of severe malaria as defined by WHO50, with the exception of anaemia and parasite density
Children who have urgent need for blood transfusion as indicated by the presence of tachypnoea, tachycardia & gallop rhythm, tender hepatomegaly
Children with known haemoglobinopathy
Children with a weight for height Z score below -3SD of WHO/NCHS standard
Enrolment in another research project
Intervention: Rotigotine
Trial phase: Phase 3
ATC code: N04BC09
SMILES: CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 191
Group description: Rotigotine transdermal patch
Eligibility criteria:
Inclusion Criteria:

Early and advanced Idiopathic Parkinson Disease with early morning motor impairment

Exclusion Criteria:

Atypical Parkinsonian syndromes
Intervention: Simvastatin
Trial phase: Not Applicable
ATC code: A10BH51 | C10AA01 | C10BA02 | C10BA04 | C10BX01 | C10BX04
SMILES: CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 78
Group description: Patients were treated with simvastatin 80 mg for 6 weeks
Eligibility criteria:
Inclusion Criteria:

Stable angina
Low-density lipoprotein (LDL) cholesterol 70-160 mg/dl

Exclusion Criteria:

Renal failure
Age>80
Simvastatin current treatment>20mg
Hepatic disease
Inflammatory diseases
Intervention: Norgestrel
Trial phase: Phase 4
ATC code: G03AA06 | G03FA10 | G03FB01
SMILES: C#CC1(O)CCC2C3CCC4=CC(=O)CCC4C3CCC21CC
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 93
Group description: Levonorgestrel IUD will be inserted immediately after completion of D&E

Levonorgestrel IUD: intrauterine insertion for arm 1 immediately after D&E procedure and for arm 2 at 3-6 weeks post-procedurem
Eligibility criteria:
Inclusion Criteria:

Gestational age from 15 weeks 0 days to 23 weeks 6 days at enrollment (time of D&E), confirmed by ultrasound
Has already consented to a D&E
Desires to use the LNG-IUD (Mirena) for contraception for 12 months or more
Willing and able to sign an informed consent
Willing to comply with the study protocol
Age greater than or equal to 18 years
Primary residency in Allegheny, Beaver, Washington, Westmoreland, Butler, Armstrong, Indiana, Fayette, Greene, or Lawrence counties of Pennsylvania

Exclusion Criteria:

Allergy to either polyethylene or levonorgestrel
Urgent need for termination of pregnancy (active bleeding or infection)
Exposure to or treatment for gonorrhea or Chlamydia within the past 90 days
Diagnosis of pelvic inflammatory disease within the past year
Presence of one or more leiomyomata greater than 3 centimeters in diameter
Uterine anomaly (other than a repaired septate uterus)
Current participation in any other intervention trial

Post-Enrollment Pre-Randomization Exclusion criteria (to be assessed at the completion of the D&E. These criteria will be used to define a group not eligible for immediate insertion. Since these complications contraindicate immediate insertion, the issue of whether immediate and delayed insertion is preferable is no longer in question.)

Uterine perforation
Hemorrhage as defined by one of the following: (1) need for transfusion; (2) estimated blood loss greater than 500 cc; (3) intrauterine placement of a Foley catheter; or (4) the use of 3 or more doses of uterotonic medications
Evidence of infection at the time of the D&E, including fever (temperature ≥ 38°C) or pus at the cervical os
Subject no longer desires a LNG-IUD
Intervention: Norgestrel
Trial phase: Phase 4
ATC code: G03AA06 | G03FA10 | G03FB01
SMILES: C#CC1(O)CCC2C3CCC4=CC(=O)CCC4C3CCC21CC
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 93
Group description: Levonorgestrel IUD will be inserted at standard time post-procedure (3-6 weeks post D&E procedure)

Levonorgestrel IUD: intrauterine insertion for arm 1 immediately after D&E procedure and for arm 2 at 3-6 weeks post-procedurem
Eligibility criteria:
Inclusion Criteria:

Gestational age from 15 weeks 0 days to 23 weeks 6 days at enrollment (time of D&E), confirmed by ultrasound
Has already consented to a D&E
Desires to use the LNG-IUD (Mirena) for contraception for 12 months or more
Willing and able to sign an informed consent
Willing to comply with the study protocol
Age greater than or equal to 18 years
Primary residency in Allegheny, Beaver, Washington, Westmoreland, Butler, Armstrong, Indiana, Fayette, Greene, or Lawrence counties of Pennsylvania

Exclusion Criteria:

Allergy to either polyethylene or levonorgestrel
Urgent need for termination of pregnancy (active bleeding or infection)
Exposure to or treatment for gonorrhea or Chlamydia within the past 90 days
Diagnosis of pelvic inflammatory disease within the past year
Presence of one or more leiomyomata greater than 3 centimeters in diameter
Uterine anomaly (other than a repaired septate uterus)
Current participation in any other intervention trial

Post-Enrollment Pre-Randomization Exclusion criteria (to be assessed at the completion of the D&E. These criteria will be used to define a group not eligible for immediate insertion. Since these complications contraindicate immediate insertion, the issue of whether immediate and delayed insertion is preferable is no longer in question.)

Uterine perforation
Hemorrhage as defined by one of the following: (1) need for transfusion; (2) estimated blood loss greater than 500 cc; (3) intrauterine placement of a Foley catheter; or (4) the use of 3 or more doses of uterotonic medications
Evidence of infection at the time of the D&E, including fever (temperature ≥ 38°C) or pus at the cervical os
Subject no longer desires a LNG-IUD
Intervention: Nesiritide
Trial phase: Phase 3
ATC code: C01DX19
SMILES: CCC(C)C1NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(Cc2ccccc2)NC(=O)C(NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C2CCCN2C(=O)C(N)CO)C(C)C)CSSCC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc2c[nH]cn2)C(=O)O)C(C)C)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3498
Group description: 0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
Eligibility criteria:
Inclusion Criteria:

Hospitalized for the management of acute decompensated heart failure (ADHF) or diagnosed with ADHF within 48 hours after being hospitalized for another reason; Diagnosis of ADHF is defined as dyspnea (difficulty breathing) at rest or dyspnea with minimal activity.

Exclusion Criteria:

At high risk for hypotension (low blood pressure); Acute coronary syndrome as primary diagnosis; History of cardiac valvular stenosis, restrictive cardiomyopathy, hypertrophic cardiomyopathy, or pericardial tamponade; Previous enrollment in a nesiritide study; Persistent, uncontrolled hypertension (SBP [systolic blood pressure] >180 mmHg).
Intervention: Citalopram
Trial phase: Phase 3
ATC code: N06AB04 | N06AB10
SMILES: CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 72
Group description: 10 mg escitalopram pill, daily for 12 weeks, for individuals entering buprenorphine treatment for opioid dependence
Eligibility criteria:
Inclusion Criteria:

opiate dependence
Ham-D > 14

Exclusion Criteria:

no psychiatric contraindications to using escitalopram
no medical contraindications to using escitalopram
methadone dose < 30
no current SSRI use
Intervention: Naltrexone
Trial phase: Phase 2 | Phase 3
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 27
Group description: intramuscular injection of Vivitrol 380 mg and Placebo

Vivitrol: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
Eligibility criteria:
Inclusion Criteria:

Adult, aged 18-60.
Meets Diagnostic and Statistical Manual IV (DSM-IV) criteria for current opiate dependence disorder of at least six months duration, supported by a positive urine for opiates and a positive naloxone challenge test if the diagnosis is unclear.
Able to give informed consent.

Exclusion Criteria:

Pregnancy, lactation, or failure in a sexually active woman to use adequate contraceptive methods.
Active medical illness which might make participation hazardous, such as untreated hypertension, acute hepatitis with serum glutamic oxaloacetic transaminase or serum glutamic-pyruvic transaminase levels >2 times normal, unstable diabetes, chronic organic mental disorder (e.g., AIDS dementia).
Active psychiatric disorder which might interfere with participation or make participation hazardous, including DSM-IV schizophrenia, bipolar disorder with mania or psychosis, and depressive disorder with suicide risk or 1 or more suicide attempts within the past year.
History of allergic reaction to buprenorphine, naloxone, memantine, naltrexone, clonidine, or clonazepam.
Currently prescribed or regularly taking opiates for chronic pain or medical illness.
Current participation in another intensive psychotherapy or substance abuse treatment program or currently prescribed psychotropic medications.
Current participation in a methadone maintenance treatment program and/or regular use of illicit methadone (>30 mg per week).
History of accidental drug overdose in the last three years or any other significant history of overdose following detoxification defined as an episode of opioid-induced unconsciousness or incapacitation, whether or not medical treatment was sought or received.
Intervention: Diclofenac
Trial phase: Not Applicable
ATC code: D11AX18 | M01AB05 | M01AB55 | M02AA15 | S01BC03 | S01CC01
SMILES: O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 218
Group description: Preservative- free Diclofenac Na 0.1 % eye drops were applied in one consecutively assigned eye of healthy volunteers four times a day for three days, after which macular thichness was measured in both subjects' eyes with the OCT .
Eligibility criteria:
Inclusion Criteria:

Adults healthy volunteers and adult patients with anterior uveitis who wish to participate.

Exclusion Criteria:

Patients with anterior uveitis who have other systemic diseases/conditions not related to their anterior uveitis, like high blood pressure, diabetes or epilepsy.
Patients with ocular comorbidity or compliactions to their anterior uveitis, such as elevated ocular pressure or glaucoma.
Previous or current macular edema or other posterior segment complications related to uveitis.
Subjects with visual acuity worse than 0.8
Subjects/patients with cataracts or other ocular media opacities
Subjects/patients who are allergic to local anesthesia or mydriatics.
Subjects/patients with high myopia/hyperopia
Subjects/patients who have had intraocular surgery, although previous uncomplicated LASIK correction for low-grade myopia were accepted.
Subjects/patients who cooperate poorly.
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 218
Group description: Benzalkonium-reserved Dexamethasone Sodium Phosphate 0.1% was applied in one consecutively assigned eye of healthy volunteers six times a day for three days, after which macular thickness was assessed in both subjects's eyes with the OCT.
Eligibility criteria:
Inclusion Criteria:

Adults healthy volunteers and adult patients with anterior uveitis who wish to participate.

Exclusion Criteria:

Patients with anterior uveitis who have other systemic diseases/conditions not related to their anterior uveitis, like high blood pressure, diabetes or epilepsy.
Patients with ocular comorbidity or compliactions to their anterior uveitis, such as elevated ocular pressure or glaucoma.
Previous or current macular edema or other posterior segment complications related to uveitis.
Subjects with visual acuity worse than 0.8
Subjects/patients with cataracts or other ocular media opacities
Subjects/patients who are allergic to local anesthesia or mydriatics.
Subjects/patients with high myopia/hyperopia
Subjects/patients who have had intraocular surgery, although previous uncomplicated LASIK correction for low-grade myopia were accepted.
Subjects/patients who cooperate poorly.